288 related articles for article (PubMed ID: 29357802)
1. Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.
Moral MEG; Siahaan TJ
Curr Top Med Chem; 2017; 17(32):3425-3443. PubMed ID: 29357802
[TBL] [Abstract][Full Text] [Related]
2. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors.
Anderson ME; Siahaan TJ
Peptides; 2003 Mar; 24(3):487-501. PubMed ID: 12732350
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases.
Yusuf-Makagiansar H; Anderson ME; Yakovleva TV; Murray JS; Siahaan TJ
Med Res Rev; 2002 Mar; 22(2):146-67. PubMed ID: 11857637
[TBL] [Abstract][Full Text] [Related]
4. Immune Modulation by Antigenic Peptides and Antigenic Peptide Conjugates for Treatment of Multiple Sclerosis.
Mahadik R; Kiptoo P; Tolbert T; Siahaan TJ
Med Res Arch; 2022 May; 10(5):. PubMed ID: 36381196
[TBL] [Abstract][Full Text] [Related]
5. Cell adhesion molecules for targeted drug delivery.
Dunehoo AL; Anderson M; Majumdar S; Kobayashi N; Berkland C; Siahaan TJ
J Pharm Sci; 2006 Sep; 95(9):1856-72. PubMed ID: 16850395
[TBL] [Abstract][Full Text] [Related]
6. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection.
Dedrick RL; Bodary S; Garovoy MR
Expert Opin Biol Ther; 2003 Feb; 3(1):85-95. PubMed ID: 12718733
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
Low PS; Henne WA; Doorneweerd DD
Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
[TBL] [Abstract][Full Text] [Related]
8. Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.
Manikwar P; Kiptoo P; Badawi AH; Büyüktimkin B; Siahaan TJ
Med Res Rev; 2012 Jul; 32(4):727-64. PubMed ID: 21433035
[TBL] [Abstract][Full Text] [Related]
9. Peptide-mediated targeted drug delivery.
Majumdar S; Siahaan TJ
Med Res Rev; 2012 May; 32(3):637-58. PubMed ID: 20814957
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of LFA-1 Peptide-Methotrexate Conjugates in Modulating Endothelial Cell Inflammation and Cytokine Regulation.
Yusuf-Makagiansar H; Yakovleva TV; Weldele M; Mahadik R; Siahaan TJ
Med Res Arch; 2023 Feb; 11(2):. PubMed ID: 37063234
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.
Chittasupho C; Siahaan TJ; Vines CM; Berkland C
Ther Deliv; 2011 Jul; 2(7):873-89. PubMed ID: 21984960
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.
Kobayashi N; Kobayashi H; Gu L; Malefyt T; Siahaan TJ
J Pharmacol Exp Ther; 2007 Aug; 322(2):879-86. PubMed ID: 17522343
[TBL] [Abstract][Full Text] [Related]
13. Assessing potential peptide targeting ligands by quantification of cellular adhesion of model nanoparticles under flow conditions.
Broda E; Mickler FM; Lächelt U; Morys S; Wagner E; Bräuchle C
J Control Release; 2015 Sep; 213():79-85. PubMed ID: 26134072
[TBL] [Abstract][Full Text] [Related]
14. Integrin crosstalk allows CD4+ T lymphocytes to continue migrating in the upstream direction after flow.
Kim SHJ; Hammer DA
Integr Biol (Camb); 2019 Dec; 11(10):384-393. PubMed ID: 31851360
[TBL] [Abstract][Full Text] [Related]
15. Emerging peptide therapeutics for inflammatory autoimmune diseases.
Briand JP; Muller S
Curr Pharm Des; 2010; 16(9):1136-42. PubMed ID: 20030611
[TBL] [Abstract][Full Text] [Related]
16. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
17. Adhesion molecules in autoimmune disease.
McMurray RW
Semin Arthritis Rheum; 1996 Feb; 25(4):215-33. PubMed ID: 8834012
[TBL] [Abstract][Full Text] [Related]
18. Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells.
Iskandarsyah ; Tejo BA; Tambunan US; Verkhivker G; Siahaan TJ
Chem Biol Drug Des; 2008 Jul; 72(1):27-33. PubMed ID: 18554252
[TBL] [Abstract][Full Text] [Related]
19. Peptide-drug conjugate-based novel molecular drug delivery system in cancer.
Zhu YS; Tang K; Lv J
Trends Pharmacol Sci; 2021 Oct; 42(10):857-869. PubMed ID: 34334251
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
